Harris aims to broaden some IRA provisions, including Medicare drug price negotiation, while Trump has adopted a more industry-friendly approach.

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.

Alimentiv, a full-service GI CRO and pioneer in IBD medical imaging solutions since 1986, is excited to announce the expansion of its partnership with Satisfai Health, a leader in AI medical solutions ...

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Data Validation and Compliance: The Sapio LIMS and ELN ensure adherence to the FDA and EMA-guided IGX assay validation approach, providing for monitoring and reporting on cut points, sensitivity, ...